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Motivation: Drug combination screening has advantages in identifying cancer treatment options with
higher efficacy without degradation in terms of safety. A key challenge is that the accumulated number of
observations in in-vitro drug responses varies greatly among different cancer types, where some tissues
are understudied than the others. Thus, we aim to develop a drug synergy prediction model for
understudied tissues as overcoming data scarcity problems.
Methods: We collected a comprehensive set of genetic, molecular, phenotypic features for cancer cell
lines. We developed a drug synergy prediction model based on multi-task deep neural networks to
integrate multi-modal input and multiple output. We also utilized transfer learning from data-rich tissues
to data-poor tissues.
Results: We showed improved accuracy in predicting synergy in both data-rich tissues and understudied
tissues. In data-rich tissue, the prediction model accuracy was 0.9577 AUROC for binarized classification
task and 174.3 mean squared error for regression task. We observed that an adequate transfer learning
strategy significantly increases accuracy in the understudied tissues.
Conclusions: Our synergy prediction model can be used to rank synergistic drug combinations in




Discovering synergistic drug combination in cancer treatment has been widely studied as it identifies
candidates with higher efficacy without degradation in terms of safety.1–4 Many previous studies show
great promises in finding potent drug combinations that cannot be identified by one drug - one target
approaches.5–10, A considerable amount of drug synergy prediction methods has been investigated
including pharmacokinetic and pharmacodynamic methods,10,11 post-treatment transcriptome,12,13 feature-
based machine learning, 5,7,8,14,15 neural networks with multi-modal data sources,4,16 and large community
efforts.17,18 These studies utilize various features such as molecular profiles, chemical structure, pre- or
post-treatment transcriptome. Their prediction target usually remains in a specific pathway, cell lines, or
tissue. These studies are usually based on single databases and the prediction was also made within the
database.3–5,18 A systematic integration of multiple drug synergy databases has been recently proposed,19,20
which shed the light on developing unbiased drug synergy prediction models.
On the developing unbiased and generalizable drug synergy prediction model, a key challenge is an
imbalance of synergy experimental data, in which the accumulated number of observations in in-vitro
drug responses varies greatly for different tissues. Traditional methods target studying commonly
observed tissues such as breast, kidney, skin, lungs.4,7,17,21–25 These methods take known drug response
data at certain cell lines and attempt to find other drugs responses at other cell lines within the same data-
rich tissues. The understudied tissues include bone, prostate, and pancreas (Fig. 1a and 1b). A number of
obstacles impede the drug response study in these tissues. For example, bone cancer drugs response has
been poorly understood due to physical difficulty of culturing bone tissues as cell lines, the rarity of the
tumors in sarcoma type, the difficulties of obtaining tumor tissue fragments from human patients for bone
metastasis, and thus the limited number of cell models.26 The lack of cell line models makes the high-
throughput screening difficult, which in turn makes these tissues even more understudied. There is,
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therefore, a critical need to develop a computational drug combination prediction tool for the
understudied tissues.
Our goal is to develop a generalizable in-silico drug synergy prediction model in understudied tissues.
The most critical challenge is data scarcity. Understudied tissues inevitably lack enough training data;
they have a limited number of experimental observations and also lack important features such as post-
treatment transcriptome. A potential way to mitigate this data scarcity problem is to utilize information
from the data-rich tissues to the data-poor tissues as these different tissues share biological commonality
partly in terms of gene expression and therefore respond drugs in similar ways.27 Several previous studies
support that anti-cancer drug sensitivity in cell lines is not tissue-specific and that tissue-specific drugs
can bring additional benefits to other tissues.28,29 Accordingly we proposed to utilize interaction between
drugs and cell lines learned from the data-rich tissues to help increase the performance of the data-poor
tissue using transfer learning. Transfer learning is to transfer knowledge (in the form of parameters in
machine learning model) from previously learned model (teacher model) with large data to new model
(student model) with fewer data. Several methods have been proposed to utilize transfer learning in drug
sensitivity prediction to link complementary data sources, different modality of auxiliary feature, and
different disease.30,31 To learn generalizable and thus transferable knowledge on drug target and cell line
gene expressions, we integrated all types of available tissues in one model with a large dataset (i.e., 4,150
drugs; 112 cell lines; 710,242 monotherapy sensitivity; 1,175,220 combinations synergy from 15 different
synergy studies).  We maximally utilized various types of multi-modal inputs (molecular, genetic,
phenotypic features) and multiple outputs (drug sensitivity and synergy) using flexible neural networks




Drug sensitivity and synergy
We used a publicly available large-scale drug synergy database from DrugComb Portal,19 which
combines 15 drug synergy studies into one integrated database including O’Neil, Cloud, ALMANAC,
NCATS Matrix, Forcina, Mathews, Phelan, Wilson, and Yohe (Table S1).3,32–38 The number of unique
drugs and cell lines were 4,150 and 112, respectively (Fig. 1). There are 2,843 experimental drugs and
1,307 FDA-approved drugs. There were a total of 710,242 monotherapy sensitivity (a pair of drug and cell
line) and 466,259 drug combinations synergy (a triplet of drug1, drug2, and cell line). For monotherapy
sensitivity we calculated relative inhibition (RI) from dosage combination matrix (Supplementary 1). For
drug combinations synergy we used Loewe synergy score (Fig. 1), which ranged from -100 (antagonistic
effect) to 75 (strong synergistic effect).39 Loewe synergy score is to quantify the excess over the expected
response if the two drugs are the same compound.40,41 We selected Loewe score for comparison with the
baseline study.4
Drug’s features
We extracted the drug's molecular and genomic features. For molecular features, we used both Molecular
ACCess System (MACCS) fingerprints42 and native chemical compounds. MACCS fingerprints contain
166 chemical structures such as the number of oxygen, S-S bonds, and rings. We used RDKit
(http://www.rdkit.org) to extract MACCS fingerprints. In addition, we represented drugs as a native
chemical structure using SMILES. SMILES is a linear notation to represent chemical compound
uniquely; in the SMILES representation atoms are represented as their atomic symbols (e.g., c for
carbon); special characters are also used to represent relationship (e.g., “=”: double bonds; “#”:triple
bonds; “.”:ionic bond; “:”: aromatic bond)43. SMILES can provide richer features space that strictly
represent functional substructures and express structural differences such as compound’s chirality 44. We
used the state-of-the-art natural language processing model, Transformer, to encode the SMILES
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sequence.45For genomic features, we integrated three different drug databases — DrugBank,46
Therapeutic Targets Database (TTD),47 and NIH-LINC48 — for complete view of drug’s target genes
(Table S2). We filtered non-human target genes in TTD.
Cell line’s features
We used the cell line’s cancer type and genomic features. There were 14 tissues including lung, ovary,
and skin and 14 cancer types including carcinoma, adenocarcinoma, and melanoma (Table S3). We also
extracted gene expression profiles by Fragments Per Kilobase of transcript per Million reads mapped
(FPKM) from CCLE and COSMIC.49,50 We found 75 cell lines with 37,260 genes from Broad Institute
and 25 cell lines with 35,004 genes from Sangar (Table S2). In total, we found 88 cell lines with 22,586
genes after excluding zero-variance genes. We normalized the FPKM values into z-score in a gene-wise
manner as FPKM varies greatly depending on gene. We only used baseline (before-treatment) gene
expression profiles without after-treatment gene profiles because our objective is to test our models in
understudied tissues, which rarely has after-treatment gene profiles.
METHODS
Method overview
Our transfer learning approach to enhance synergy prediction in data-poor tissue is to transfer parameters
from a pre-trained general prediction model to the specific tissue’s prediction models. We first learned the
general prediction model with data-abundant tissues (including brain, breast, colon, endometrium,
hematopoietic and lymphoid, kidney, lung, ovary, and skin) from the pooled drug synergy databases
containing the 15 different databases. We used neural networks as the prediction model due to its
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flexibility in parameter sharing. The prediction model for the data-poor tissue was initialized with the pre-
trained general model’s parameters and re-trained with its own data accordingly.
General prediction model
Our objective is to predict whether unobserved drug combinations have synergistic effects in a given cell
line and provide a list of combinations that researchers can prioritize for experiments. We formulated it as
a prediction problem. Given an experimental block : = { , , }of drug combination ( , )
and cell line , the prediction model is a function  such that
≈ ( , , ),
where is the synergy score of the drug combination. In addition to the synergistic effect, we used
the drug's monotherapy sensitivity as another prediction objective to boost the synergy prediction. For
monotherapy sensitivity in the cell line, the prediction model is :
  ≈ ( , ) and   ≈ ( , ),
where is the sensitivity score of drug in cell line . We jointly optimize sensitivity and synergy
as multi-task learning. To incorporate multimodal sources of inputs and formulate nonlinear relationships
between chemical and genomic features, we used deep neural networks as the prediction function. Our
prediction model consists of drug encoders (Fig. 2a), cell line encoder (Fig. 2b), and merging layers (Fig.
2c) for final prediction in an end-to-end manner. Using the estimated drug response, we can rank drug
combinations at a cell line that are expected to have synergistic effect.
Drug encoder
Drug encoder learns an embedding representation of each drug or . Each drug’s features are
{MACCS fingerprints, canonical SMILES, target genes} (Table 1). Binary indicators of MACCS
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fingerprints were used as raw input. Binary vectors of target genes were represented as compressed
embedding with a single layer of denoising autoencoder.51 As SMILES has variable length, we need more
careful consideration. We used Transformer encoder, a natural language processing model that convert
the sequence into a representation.45 Each symbol in SMILES were first represented as one-hot vectors
with size of (#SMILES length * #unique symbols), where #unique symbols was 48 and the maximum
SMILES length was 288. The symbol’s one-hot vector was then represented as embedding. This
embedding sequence was fed into a separate Transformer encoder, which consists of a multi-head
attention layer and feed-forward layer with repeated residual connections. Once we derived all the
embedding representations, they were concatenated into one and fed into two feed forward layers with
Relu activation and dropout (Fig. 2a).
Table 1. Multimodal input and multi-task output to predict drug response. SMILES=Simplified




Drug features MACCS fingerprint 166 Binary indicator vector




Target gene 24,342 (Total number
of unique genes)
Binary indicator vector










Relative inhibition Continuous value or
binarized value at 50
Combination synergy Loewe synergy
score
Continuous value or
binarized value at 30
Cell line encoder
Cell line encoder learns an embedding representation of each cell line .  Each cell line’s features are
{cancer type, gene expressions} (Table 1). To combine the multimodal inputs, we derived embedding
from each source and merged into one embedding. The cancer types were represented as the same sized
embedding. The gene expression of each cell line was represented as compressed embedding from the
normalized FPKM values with 1 layer of denoising autoencoder. We concatenated all three embeddings
into one and fed them into two feed forward layers with Relu activation and dropout (Fig. 2b).
Note that we did not include drug ID or cell line ID as an input. The IDs are useful in collaborative
filtering techniques, which assumes that two drugs will react to a cell line similarly if these drugs have
responded similarly to certain cell lines. In contrast, our focus was to derive transferable general
knowledge in prediction models from data-abundant domain to data-scarce one. The cell lines between
the two domains are disjoint to each other in most cases (cold start for all cases), and the data-scarce
tissues usually do not have a past drug response history.
Merging layers
For synergy prediction, we merged embedding representations of , ,  into one and fed them into
two feed forward layers with Relu activation. For sensitivity prediction, we merged embedding




We trained the model as multi-task learning that predicts synergy and sensitivity simultaneously. For
combination synergy prediction, the training loss was mean squared error (MSE):
= ||  − ( , , ) ||2
where is the synergy score. The training loss for monotherapy  ( , ) and ( , ) was
similarly defined:
= ||  − ( , ) ||2 + ||  − ( , ) ||2
for all drugs and cell lines in the training set. In addition to these regressions, we also developed
classification models. We first binarized the drug responses by setting a threshold. That is, = 1if
> ℎ ℎ ; 0 otherwise, and = 1if > ℎ ℎ ; 0 otherwise. The
synergy and sensitivity threshold were set at 30 and 50 following the previous study.4,52 Then the
classification model’s training loss was binary cross entropy:
=  − ( ( , , )) −  (1− ) [1 − ( ( , , ))]
=  − ( ( , )) −  (1− ) [1 − ( ( , ))]  −
( ( , ))−  (1− ) [1− ( ( , ))]
where  is a sigmoid function. We alternated the two optimization tasks with respect to synergy or
sensitivity in every epoch. That is, we first minimized with all training batches and then
switched to  for the next training round. Optimizer was adaptive gradient descent with
Autograd in PyTorch 1.3.0.
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Fine-tuning to data-poor tissues
We focused on transfer learning from the pooled data-rich tissues to bone and prostate (Fig. 3a),
respectively. For the transfer learning experiments, we chose the bone and prostate tissue (number of
observations > 1,000) over soft tissue, endometrium, and pancreas (number of observations < 1,000) (Fig.
1a), because they have too few observations to build their own prediction model for comparative
experiments. We first pre-trained the general drug response prediction model with the data-rich tissues to
learn the underlying mechanism between drugs and cell lines, and built a separate prediction model for
specific tissue of interest (i.e., bone or prostate), transferred the pre-trained model parameters from the
general model, and fine-tuned the specific tissue models’ parameters. Possible fine-tuning strategies
include i) retraining all the parameters, ii) fixing drug encoders & retraining cell line encoders and
merging layers, iii) fixing drugs and cell line encoders & retraining merging layers, and iv) no retraining
at all. We compared the accuracy of the four different strategies in each tissue and reported the best one.
Evaluation
Training and test set. We evaluated the general and specific prediction models with cross and external
validation. For cross validation, we randomly separated the pooled databases into train (80%) and test set
(20%) (Fig. 3b). For external validation, we set aside one independent database as a test set and used the
remaining pooled databases as a training set (Fig. 3b); the independent test set had only a few overlapping
cell lines or drugs with that of the training set (e.g., nine cell lines and 36 drugs were common in training
and test sets in data-rich tissues). Each data-poor tissue (bone and prostate) had four distinct cell lines,
respectively (Fig 1ab); different tissues sometimes shared drugs, such as the bone tissue sharing 1,437
drugs and the prostate tissue sharing 127 drugs with the data-rich tissues.
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Accuracy measures. We measured accuracy of the regression and classification task. The regression
accuracy measure was the mean squared error (MSE); the classification accuracy measures were area
under the receiver operating curve (AUROC) and area under precision-recall curve (AUPRC).
Baselines. We compared our accuracy with two baseline methods — i) DeepSynergy that utilizes deep
neural networks using drug’s descriptors and cell line’s gene expression on O’Neil database4 and
ALMANAC+XGBoost that utilizes gradient boosting trees.5 We also implemented the collaborative
filtering method that uses drugs and cell lines ID as input to compare our contents-based approach with
collaborative approach. Benchmark accuracy values of various machine learning methods (including
support vector machines, gradient boosting machines, and random forest) are listed in the referred paper.4
Note that each training or test set was a triplet { , , }of the drug pair and cell line in
corresponding tissue. We did not report sensitivity prediction accuracy because the train/test split was
disjoint in terms of synergy triplets but sometimes overlapped in terms of sensitivity pairs. For example,
let us say we split the data as { 1 , 2 , 1} in the training set and { 1 , 3, 1} in the test set for synergy
prediction.  This split implies { 1, 1}, { 2 , 1} in training and { 1 , 1}, { 3 , 1} in the test set for
sensitivity prediction. Due to the overlapped pairs { 1, 1}, the sensitivity prediction accuracy can be too
optimistic.
RESULTS
Prediction accuracy of general model
We evaluated the accuracy of our synergy prediction models. First experiment was to evaluate the
accuracy of general models trained and tested with data-rich tissues (Table 2). We achieved {0.9577
AUROC, 0.8335 AUPRC, 132.4 MSE} for cross validation (randomly split from 15 pooled databases)
and {0.6376 AUROC, 0.5564 AUPRC, 742.1 MSE} for external validation (i.e., trained with 14 pooled
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databases; tested with O’Neil). The collaborative filtering method based on drugs and cell IDs showed
lower accuracy compared to our multimodal-contents-based model. The lower accuracy in external
validation compared to cross validation might be partly due to different experimental settings on
measuring the drug responses scores and gene expression values across various synergy databases.
We trained and tested our model with O’Neil database in particular to compare our model’s accuracy with
DeepSynergy.4 Our model achieved significantly higher AUROC/AUPRC and lower MSE —
DeepSynergy showed {0.90 AUROC, 0.59 AUPRC, 255.5 MSE}; whereas our proposed model showed
{0.95 AUROC, 0.94 AUPRC, 181.7 MSE}. In addition, we also trained our model with the ALMANAC
database to compare our accuracy with that of NCI-ALMANAC + XGBoost model.5 Our model achieved
{0.97 AUROC, 0.84 AUPRC, 75.4 MSE}; whereas the baseline XGBoost model achieved 77.8 MSE.
The increased accuracy was mainly due to more diverse multi-modal features (such as target genes and
native SMILES) and multi-task learning with the monotherapy sensitivity.
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Table 2. Drug synergy prediction accuracy for data-rich tissues. Cross validation with randomly split
train/test from the 15 pooled databases. External validation with the O’Neil for test and the remaining 14
pooled databases for training. For classification tasks, AUROC and AUPRC were computed after
binarizing synergy at threshold 30. AUROC=area under the receiver operating curve; AUPRC= area
under the precision-recall curve; MSE=mean squared error.


























O’Neil 0.6376 0.5564 742.1
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Prediction accuracy of specific model with transfer learning
In next experiments we moved our focus to understudied tissues. These experiments compared the four
different strategies on transferring model parameters from data-rich tissues to bone and prostate
respectively. We also compared accuracy with and without the transferred model parameters. We found
that an adequate transfer learning increases accuracy in both bone and prostate (Table 3). In external
validation of bone cell lines, we achieved {0.6647 AUROC, 0.4150 AUPRC, 297.4 MSE} without
transfer learning and {0.8015 AUROC, 0.4676 AUPRC, 195.9 MSE} with transfer learning (transferred
all parameters and no fine-tuned). In the external validation of prostate cell lines, we achieved {0.6505
AUROC, 0.5220 APPRC, 528.5 MSE} without transfer learning and {0.8542 AUROC, 0.7804 AUPRC,
327.9 MSE} with transfer learning (fixed drug and cell line encoders and retrained last merging layers).
Table 3. Drug synergy prediction accuracy for bone and prostate cancer (data-poor tissue) with different
transfer learning strategies in cross or external validation.

































parameters 0.9928 0.9628 47.4
ALMANAC ONEIL
No transfer 0.6505 0.5220 528.5
Fix encoders
and retrain last
merging layers 0.8542 0.7804 327.9
Ranking
We listed predicted drug combinations for bone and prostate using the externally validated model. We
selected top 20 combinations based on estimated probability of being synergistic (Table 4, S3). For the
bone cell lines, among the top 20 five combinations were actually synergistic (5/20=25% hit) in the
independent validation set (ES Naampt_PARP). Considering the fact that only 1.56% of combinations are
synergistic in bone, our model effectively ranked synergistic drug combinations. For the prostate cell
lines, all top 20 combinations were actually synergistic in the independent O’Neil database (only 2.15%
of combinations are synergistic in the prostate).
Table 4. Top 5 drug combinations in bone and prostate. The bone model was trained with DIPG and ES
(FAKi/AURKi), and tested with ES (Naampt_PARP). The prostate model was trained with ALMANAC
and tested with O’Neil. “Hit” was marked if the predicted drug combinations show Loewe synergy score
>30. Full list of top 20 drug combinations in Table S4.
Drug1 Drug2 Cell line Hit?
Bone
17
AZD1775  AZACITIDINE  TC-71
ZINC34894448  ZINC34894448  TC-71 ✓
ZINC34894448  ZINC34894448  EW-8
AZD1775  AZACITIDINE  EW-8
thapsigargin  thapsigargin  TC-71 ✓
Prostate
TOPOTECAN  BEZ-235  LNCAP ✓
GELDANAMYCIN  BEZ-235  LNCAP ✓
DOXORUBICIN  BEZ-235  LNCAP
✓
BORTEZOMIB  BEZ-235  LNCAP
✓
5-FU  BEZ-235  LNCAP ✓
DISCUSSION
The objective of this study was to develop the drug combination synergy prediction model, which can be
used even in the understudied tissue with less observation. To meet this end, we i) collected a
comprehensive set of multimodal features from multiple databases, ii) integrated the multimodal features
and multiple tasks using deep neural networks, iii) transferred the prediction model from data-rich tissues
to data-poor one. As a result, the proposed model predicted drug synergy accurately with 0.8015 AUROC
for bone and 0.8542 AUROC for prostate in external validation with an adequate transfer learning
strategy.
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Main contribution of our study is that we tackle understudied but critical tissues for drug synergy
prediction. The difficulty of obtaining cell lines in these understudied tissues has limited the in-vitro
experiments, which consequently become an obstacle to drug development in these tissues. As we
focused on understudied tissues, we should avoid using post-treatment gene expression profiles as an
input feature. The post-treatment gene expression is the most powerful feature to estimate drug response,
but it is only accessible after drug compounds are tested in cell line.7 Our drug response prediction model
was able to successfully bypass the post-treatment features while achieving competitive accuracy.
Although our study’s focus is on predicting synergy in understudied tissues, our model achieved
improved accuracy even on general data-rich tissues than that of the baseline model. This increased
accuracy is possibly due to the large-scale and multi-modal data with multi-task optimization. We used
the 15 complementary drug synergy databases including the NCI-ALMANAC, Cloud, O’Neil, and
NCATS Matrix. We incorporated diverse and comprehensive multi-modal sources of features. This large-
scale data collection allowed us to maximize the power of data-driven computational models based on
deep neural networks.
Our model was designed to predict combination synergy together with monotherapy sensitivity
simultaneously. Here monotherapy sensitivity was an auxiliary output to boost accuracy of synergy
prediction. A previous study uses monotherapy sensitivity as an input feature to predict synergy,7 but
understudied tissues do not have enough experimental observation including monotherapy response
features. To utilize this partial input feature in data-rich tissues (not in data-poor tissues), we used the
monotherapy sensitivity as an auxiliary output in data-rich tissue models so that we can still transfer the
information to data-poor tissues via the model parameters when minor tissues do not have monotherapy
sensitivity.
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The major limitation of this study is that the general prediction model was not able to achieve high
accuracy in external validation. A possible explanation for this might be that the various synergy studies
and various tissues may have different experimental settings on measuring the drug responses and gene
expressions values, thus validation on the mixed tissues in the independent synergy experiment could
cause the discrepancy in the predicted and observed values.
In conclusion, our model is an end-to-end drug synergy prediction model that learns interaction between
drugs and cell lines. Based on the fact that different tissues share common gene expression and therefore
respond to drugs in similar ways, we used transfer learning from data-rich tissues to data-poor tissues to
make the synergy prediction model work in data-poor tissues. As a future work, our drug prediction
model for understudied tissues can potentially shed light onto other diseases that share drug targets and
underlying mechanisms and offer a novel way of efficient and low-cost drug discovery.
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FIGURE LEGENDS
Figure 1. Summary statistics of the DrugComb database. (a) Number of drug combinations and (b) cell
lines in each tissue. ‘Hem&lymp’ = hematopoietic and lymphoid tissue. Data-rich tissues include
hematopoietic and lymphoid, lung, skin, ovary, kidney, brain, breast, and colon, which have more than
20,000 drug combination tests with more than 5 different cell lines per each tissue. Data-poor tissues
include prostate and bone, which have less than 15,000 drug combination tests within 3 or 4 cell lines per
tissue. Soft tissue, endometrium, and pancreas have less than 1,000 drug combination tests within less
than 3 cell lines per tissue. (c) Number of tested drugs that overlap between tissues. Drugs for each tissue
are rarely overlapped with drugs for other tissues except the brain, hematopoietic and lymphoid tissue,
bone, and lung. (d) Distribution of monotherapy sensitivity (i.e., relative inhibition) (e) Distribution of
combination synergy score (f) Distribution of sensitivity and synergy. Concentrated and dense spikes lie
in relative inhibition between 10-50, implying that many experiments have been performed within the
relative inhibitions between 10-50. Loose spikes lie in relative inhibition below 0. Here we set the relative
inhibition’s binarization threshold at 50 as synergy scores show different distribution after 50.
Figure 2. Drug synergy prediction model. (a) Drug encoder. It learns an embedding representation of a
drug. Inputs are MACCS fingerprints, canonical SMILES, and target genes. (b) Cell line encoder. It
learns an embedding representation of a cell line. Inputs are cancer type and gene expressions. (c)
Merging drug encoder and cell line encoder. Sensitivity was an auxiliary output to boost synergy
prediction.
Figure 3. Transfer learning for understudied tissue. (a) Transfer model parameters from data-rich tissues
to data-poor tissue such as bone and prostate (b) Train/test split for data-rich tissues and data-poor tissue.
Cell lines from different tissues are disjoint. Some cell lines from different tissues sometimes share drugs.
